Research programme: paracrine gene therapy - Renova

Drug Profile

Research programme: paracrine gene therapy - Renova

Alternative Names: AAV8.UCn2; Adeno-associated virus 8 vector encoding urocortin 2 - Renova Therapeutics; RT-110; RT-200; RT-210; RT-220; RT-230; RT-300; Urocortin-2 gene therapy - Renova

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California, San Diego
  • Developer Renova Therapeutics
  • Class Gene therapies
  • Mechanism of Action Adenylate cyclase stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Heart failure; Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 18 Jul 2017 Pharmacodynamics and safety data from preclinical trials in Type 2 diabetes mellitus presented at American Heart Association's Basic Cardiovascular Sciences Scientific Sessions 2017 (AHA-2017)
  • 17 Jul 2017 Renova Therapeutics plans a first-in-human, dose-escalation trial of RT 200 for Type 2 diabetes in 2018
  • 21 Feb 2017 Renova Therapeutics has patent protection for Urocortin 2 gene construct in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top